(Q47996009)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Albert Oriol

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Marcos González Díaz

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Ramón García-Sanz

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

María E Sarasquete

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Joaquin Martinez-Lopez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M. Carmen Chillón

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

María-Belén Vidriales

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

N Puig

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

A Balanzategui

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

B Paiva

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

H García

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

S Fumero

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

C Jiménez

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

E Sebastián

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

L Marín

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M A Montalbán

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M V Mateos

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

L Palomera

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

J de la Rubia

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

J Bladé

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

J J Lahuerta

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

J F S Miguel

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

17 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

391-397

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2013.217

5 March 2020

exact match

0 references

cites work

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

The role of complete response in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Importance of achieving a complete response in multiple myeloma, and the impact of novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Individualizing treatment of patients with myeloma in the era of novel agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Extramedullary disease in plasma cell myeloma: the iceberg phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.217

Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma

21 January 2018

1 reference

12 December 2020

Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.

1 reference

12 December 2020

Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia

1 reference

12 December 2020

Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

1 reference

12 December 2020

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

1 reference

12 December 2020

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

12 December 2020

Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma

1 reference

12 December 2020

Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells

1 reference

12 December 2020

Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation

1 reference

12 December 2020

Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma

1 reference

12 December 2020

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

1 reference

12 December 2020

The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter

1 reference

12 December 2020

Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR

1 reference

12 December 2020

Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.

1 reference

12 December 2020

Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation

1 reference

12 December 2020

Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia

1 reference

12 December 2020

Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2013.217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23860448%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference